Biogen and Tokyo-based pharmaceutical company Eisai’s Alzheimer’s drug, which recently scored a win in a phase 3 trial by slowing cognitive decline by 27 percent among mild disease patients, has the potential to reverse the course of Alzheimer’s research, The Wall Street Journal reported Sept. 28.
